News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
307,817 Results
Type
Article (8460)
Company Profile (101)
Press Release (299256)
Section
Business (105724)
Career Advice (636)
Deals (18388)
Drug Delivery (20)
Drug Development (31921)
Employer Resources (42)
FDA (4741)
Job Trends (5824)
News (160709)
Policy (10201)
Tag
2024 BioCapital Digital (4)
2024 BioMidwest Digital (4)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (5)
2024 Biotech Beach Digital (7)
2024 Biotech Beach Standard (3)
2024 Genetown Digital (6)
2024 Genetown Standard (4)
2024 Lone Star Bio Digital (1)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (1)
2025 Lone Star Bio Digital (2)
2026 Biotech Bay Standard (1)
Academia (534)
Accelerated approval (2)
Adcomms (4)
Allergies (22)
Alliances (22595)
ALS (38)
Alzheimer's disease (474)
Antibody-drug conjugate (ADC) (33)
Approvals (4764)
Artificial intelligence (75)
Autoimmune disease (8)
Automation (5)
Bankruptcy (126)
Best Places to Work (4440)
BIOSECURE Act (13)
Biosimilars (17)
Biotechnology (100)
Bladder cancer (22)
Brain cancer (12)
Breast cancer (100)
Cancer (800)
Cardiovascular disease (32)
Career advice (555)
Career pathing (6)
CAR-T (69)
Cell therapy (215)
Cervical cancer (7)
Clinical research (26335)
Collaboration (338)
Compensation (225)
Complete response letters (4)
COVID-19 (660)
CRISPR (13)
C-suite (147)
Cystic fibrosis (39)
Data (898)
Depression (12)
Diabetes (80)
Diagnostics (2488)
Digital health (4)
Diversity, equity & inclusion (15)
Drug discovery (49)
Drug pricing (11)
Drug shortages (2)
Duchenne muscular dystrophy (25)
Earnings (46153)
Editorial (6)
Employer branding (6)
Employer resources (43)
Events (54202)
Executive appointments (430)
FDA (5157)
Featured Employer (15)
Fibrodysplasia Ossificans Progressiva (1)
Frontotemporal dementia (5)
Funding (336)
Gene editing (30)
Generative AI (6)
Gene therapy (104)
GLP-1 (183)
Government (683)
Guidances (22)
Healthcare (5949)
Huntington's disease (6)
IgA nephropathy (9)
Immunology and inflammation (29)
Indications (13)
Infectious disease (699)
Inflammatory bowel disease (67)
Inflation Reduction Act (3)
Influenza (19)
Intellectual property (43)
Interviews (68)
IPO (9314)
IRA (7)
Job creations (1591)
Job search strategy (512)
Kidney cancer (6)
Labor market (11)
Layoffs (126)
Leadership (5)
Legal (2796)
Liver cancer (20)
Lung cancer (79)
Lymphoma (60)
Management (13)
Manufacturing (113)
MASH (31)
Medical device (4124)
Medtech (4125)
Mergers & acquisitions (9378)
Metabolic disorders (202)
Multiple sclerosis (29)
NASH (6)
Neurodegenerative disease (24)
Neuropsychiatric disorders (4)
Neuroscience (667)
NextGen: Class of 2025 (2253)
Non-profit (920)
Northern California (1370)
Now hiring (6)
Obesity (97)
Opinion (63)
Ovarian cancer (43)
Pain (26)
Pancreatic cancer (26)
Parkinson's disease (54)
Partnered (8)
Patents (67)
Patient recruitment (46)
Peanut (15)
People (33288)
Pharmaceutical (12)
Pharmacy benefit managers (1)
Phase I (8933)
Phase II (11905)
Phase III (7978)
Pipeline (650)
Podcasts (2)
Policy (28)
Postmarket research (752)
Preclinical (3700)
Press Release (72)
Prostate cancer (39)
Psychedelics (5)
Radiopharmaceuticals (140)
Rare diseases (119)
Real estate (2871)
Recruiting (17)
Regulatory (7283)
Reports (18)
Research institute (534)
Resumes & cover letters (88)
Rett syndrome (3)
RSV (4)
Schizophrenia (35)
Series A (57)
Series B (41)
Service/supplier (2)
Sickle cell disease (17)
Southern California (1146)
Special edition (2)
Spinal muscular atrophy (60)
Sponsored (7)
Startups (1690)
State (1)
Stomach cancer (3)
Supply chain (21)
Tariffs (3)
The Weekly (2)
United States (10725)
Vaccines (105)
Venture capitalists (9)
Webinars (7)
Weight loss (37)
Women's health (5)
Worklife (2)
Date
Today (24)
Last 7 days (323)
Last 30 days (1283)
Last 365 days (16232)
2025 (4044)
2024 (17211)
2023 (19670)
2022 (26069)
2021 (27353)
2020 (24257)
2019 (17595)
2018 (13611)
2017 (14030)
2016 (13033)
2015 (16278)
2014 (12833)
2013 (10435)
2012 (11337)
2011 (12055)
2010 (11620)
Location
Africa (285)
Alabama (36)
Alaska (2)
Arizona (79)
Arkansas (3)
Asia (17128)
Australia (3137)
California (3015)
Canada (998)
China (155)
Colorado (96)
Connecticut (120)
Delaware (44)
Europe (37180)
Florida (362)
Georgia (52)
Idaho (29)
Illinois (210)
India (9)
Indiana (137)
Iowa (2)
Japan (76)
Kansas (34)
Kentucky (10)
Louisiana (6)
Maine (40)
Maryland (372)
Massachusetts (2371)
Michigan (142)
Minnesota (190)
Mississippi (1)
Missouri (28)
Montana (16)
Nebraska (13)
Nevada (25)
New Hampshire (20)
New Jersey (734)
New Mexico (10)
New York (768)
North Carolina (503)
North Dakota (5)
Northern California (1370)
Ohio (84)
Oklahoma (7)
Oregon (7)
Pennsylvania (601)
Puerto Rico (3)
Rhode Island (12)
South America (428)
South Carolina (5)
Southern California (1146)
Tennessee (48)
Texas (358)
Utah (71)
Virginia (49)
Washington D.C. (13)
Washington State (381)
West Virginia (2)
Wisconsin (23)
307,817 Results for "minerva biotechnologies corporation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates
February 26, 2025
·
7 min read
Drug Development
Minerva’s Schizophrenia Candidate Rejected by FDA in Complete Response Letter
The FDA has rejected Minerva Neurosciences’ treatment for negative symptoms in schizophrenia, noting a lack of data and other factors that led to the Complete Response Letter.
February 27, 2024
·
2 min read
·
Tyler Patchen
Business
Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates
Minerva Neurosciences, Inc. today reported business updates and financial results for the first quarter of 2024 ending March 31, 2024.
May 1, 2024
·
6 min read
Press Releases
Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates
November 5, 2024
·
6 min read
Business
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates
Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the fourth quarter and year ended December 31, 2023.
February 22, 2024
·
6 min read
Business
Minerva Surgical Reports Third Quarter 2023 Financial Results
Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company), a women’s health company focused on solutions to meet the distinct uterine healthcare needs of women, today reported third quarter financial results for the period ended September 30, 2023.
November 13, 2023
·
10 min read
Genetown
Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia
Minerva Neurosciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to the Company’s New Drug Application (NDA) for roluperidone for the treatment of negative symptoms in patients with schizophrenia.
February 27, 2024
·
6 min read
Press Releases
Minerva Neurosciences Reports Second Quarter 2024 Financial Results and Business Updates
August 6, 2024
·
6 min read
Business
Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates
Minerva Neurosciences, Inc. reported business updates and financial results for the third quarter ended September 30, 2023.
November 7, 2023
·
6 min read
Business
Minerva Surgical Reports Second Quarter 2023 Financial Results
Minerva Surgical, Inc. reported second quarter financial results for the period ended June 30, 2023.
August 2, 2023
·
10 min read
1 of 30,782
Next
